NEW YORK ─ San Diego-based Cardea Bio on Monday announced a collaboration agreement with the Siemens Healthineers Center for Innovation in Diagnostics to assess the feasibility of developing biosensor testing applications for Cardea's BPU Platform.
The BPU, short for Biosignal Processing Unit, is a semiconductor that can instantly translate streams of multiomics signals into digital information, Cardea said.
Under the agreement, the collaborators will optimize and test a next-generation SARS-CoV-2 immunoassay, the firm said, adding that hardware, software, wetware, and know-how will be transferred to Siemens Healthineers' facilities to enable use of the BPU Platform and experimentation with it.
Financial and other terms of the agreement were not disclosed.
"The ultimate goal of this project … is creating a multiomics diagnostic platform for point-of-care use cases," Rob Lozuk, Cardea's chief business officer, said in a statement.
If successful, Erlangen, Germany-based Siemens Healthineers and Cardea could expand their collaboration to include the simultaneous measurement of antigens and detection of amplification-free RNA, Cardea said.